Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00061126 · ClinicalTrials.gov registry record · Phase 2
ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body
A Phase 2 study, sponsored by Abgenix.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00061126 is a Phase 2 study that has completed, run by Abgenix. The registered enrollment target is 50 participants.
The verdict
NCT00061126, a Phase 2 study, has completed, sponsored by Abgenix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
A clinical trial examining the safety and effectiveness of ABX-EGF when given to patients with prostate cancer with or without tumor in other parts of the body. Patients will be treated for a maximum of 48 doses (6 treatment courses; 8 doses per course) or until evidence of progressive disease.
Interventions
- DRUG ABX-EGF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2003-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00061126
The ClinicalTrials.gov registry entry for NCT00061126 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abgenix, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABX-EGF is the first listed.
NCT00061126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00061126 about?
NCT00061126 is a clinical study titled "ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body". A clinical trial examining the safety and effectiveness of ABX-EGF when given to patients with prostate cancer with or without tumor in other parts of the body. Patients will be treated for a maximum of 48 doses (6 treatment courses; 8 doses per course) or until evidence of progressive disease.
What is the current status of trial NCT00061126?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2003-04.
What interventions are being tested in trial NCT00061126?
The interventions under investigation include: ABX-EGF (DRUG).
Who is sponsoring clinical trial NCT00061126?
This trial is sponsored by Abgenix, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.